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Abstract
Purpose: The purpose of this quality improvement project was to determine if an evidence-based
educational toolkit and an electronic reminder system would increase the rate of HPV
vaccination among male adolescents, age 11-18 years old in an urban pediatric clinic.
Background & Significance: HPV is one of the most commonly reported sexually transmitted
infections in the United States. The safety and efficacy of the HPV vaccine have been established
and approved for both males and females. Despite recommendations, vaccination rates among
adolescent males remain lower compared to females.
Methods: An evidenced-based educational toolkit from the CDC along with an electronic
reminder that flags patients due for vaccines, prompting staff to make vaccine recommendations,
was implemented. This QI project utilized a retrospective review of 100 male patient charts preand post-intervention.
Results: A significant increase in provider’s knowledge and recommendations for HPV
vaccination from 53% to 74.4%, and 66.7% to 100%, respectively, contributed to a 49% increase
in HPV vaccination rates post-intervention.
Conclusion: The study showed that an evidence-based educational brochure and reminder system
was effective in increasing HPV vaccination rates among adolescent males at an urban pediatric
practice.
Keywords: HPV vaccine, reminder systems, patient education, health promotion,
educational toolkit
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Human papillomavirus (HPV) is one of the most commonly reported sexually transmitted
infections (STI), occurring in both men and women in the United States (Centers for Disease
Control and Prevention [CDC], 2015a ; Dunne, Markowitz, Saraiya, Stokley, Middleman,
Unger, & Iskander, 2014). Currently, 79 million people are living with the human papillomavirus
(HPV) in the United States (U.S.). There are about 14 million new HPV infections, and 26,800
new cases of HPV-related cancers occurring annually (CDC, 2015a; Dunne et al; Markowitz,
Dunne, Saraiya, Chesson, Curtis, Gee, & Unger, 2014). Approximately 80% of sexually active
individuals will come in contact with the virus at some point in their lives. HPV can cause
diseases such as cervical cancer, genital warts, as well as oral and anogenital cancers in both
males and females (Markowitz et al., 2014). While HPV is categorized as a sexually transmitted
infection and the consistent use of condoms can decrease the spread of HPV, the virus can also
be transmitted through direct skin to skin contact and transferred without intercourse (National
Institutes of Health, 2013). Therefore, the most promising approach to protect against HPV
infection is through vaccination. HPV vaccines have been found to be very effective with the
potential to reduce HPV-related diseases when given before the first sexual encounter in both
males and females (Crowe, Pandeya, Brotherton, Dobson, Kisley, Lambert, & Whiteman, 2014).
The incidence of STI infection is highest among men and women ages 15 to 24 years
(Fernandez, Allen, Mistry, & Kahn, 2010; CDC, 2013a), and half of the reported new infections
in the United States occur among this age group (CDC, 2013a). While the occurrence of HPVrelated diseases is less common in males than females, the incidence of HPV transmission
among males is on the rise (Chaturvedi et al., 2011). It has been estimated that annually, more
than 1,168 males are diagnosed with penile cancer, 1,750 with anal cancer, and 12,638 are
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diagnosed with oropharyngeal cancer, with the highest incidence occurring among Hispanic
males (CDC, 2016b).
The rate of vaccine administration among adolescent males is much less than among
females. According to the CDC (2015b), 50% of U.S. male adolescents aged 13 to 17 years had
received at least one dose of the vaccine, but only 28% of them completed the series. These rates
are a stark contrast to vaccination rates for female adolescents aged 13 to 17 years where 63% of
U.S. females received at least one dose of the HPV vaccine, and 42% of them completed the
three-dose series (CDC, 2015b). The rate of HPV vaccination in Texas is well below the national
average with 50.7% of females having received one dose, while 33.9% completed the series. For
males, only 36.6% initiated the vaccine in 2014, and 17.7% completed the series (French &
Zumbrun, 2016). In Bexar County, the rate is even lower in comparison to other counties in
Texas; only 30.8% of females and 15% of males received at least one dose (French & Zumbrun,
2016).
Statement of the Problem
HPV is one of the most commonly acquired sexually transmitted infections and is one of
the most expensive to treat, due to the volume of new infections that are diagnosed each year
(CDC, 2013b). Many adolescents will be exposed to HPV within the first year of becoming
sexually active (Daley, 2011). As a result, the need to improve HPV vaccination rates among
adolescent males is a public health issue that healthcare providers must address during clinic
appointments.
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Background and Significance
The review of literature related to HPV revealed that there are currently 100 different
types of HPV, 30 of which are known to be transmitted sexually and at least 40 are known to
infect the genital area (CDC, 2017a; McCutcheon, 2009). Once exposed, an individual may be
infected with more than one type of HPV at the same time. When compared with other STIs,
HPV cannot be cultured, and often individuals are asymptomatic at the time of diagnosis. There
is no known cure; treatment is geared towards controlling the number of visible lesions,
regardless of the anatomical site (McCutcheon, 2009).
Protection against the types of HPV responsible for the majority HPV-related cancers is
the most preferred approach to reduce the incidence of HPV among males and females, an action
that addresses a vital issue in preventative medicine. Vaccinating males against HPV can be
effective not only for the male but each sexual partner. Furthermore, the effectiveness of the
HPV vaccine can be better achieved if the vaccination series is initiated and completed before
the initiation of sexual activity (Dobson, McNeil, Dionne, Dawar, Ogilvie, Krajden, & Young,
2013; Spleen, Kluhsman, Clark, Dignan, & Lengerich, 2012).
The Advisory Committee on Immunization Practices recommends that the Human
Papillomavirus (HPV) vaccine series be routinely given to all males and females between the
ages of 11 to 21 years. Nevertheless, the rate of HPV vaccine initiation and series completion
rates among the adolescent population in Texas and nationally remains below the Healthy People
2020 goal of 80% (Department of Health and Human Services [DHHS], 2015).
When compared with females, the rate of HPV initiation among males is lower statewide
and nationally. Despite the ACIP’s public health recommendations and the positive effect of the
HPV vaccine, disparities in the uptake of the HPV vaccine among males persist (DHHS, 2015).
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Both state and national vaccination programs continue to struggle and have yet to reach the
Healthy People 2020 goals of 80% vaccination coverage (French & Zumbrun, 2016). For this
project, the focus was on male adolescents between the ages of 11 and 18 years.
Practice Assessment
Nationally, there are no federal or state regulations in the United States that mandate the
HPV vaccine for all adolescents. Many healthcare providers continue to present the HPV vaccine
as an optional vaccination as compared to those vaccinations that are mandated (Price, 2017). As
a result, there are numerous instances of missed opportunities for HPV vaccination. Additionally,
healthcare providers are reluctant to engage in discussions regarding HPV and the vaccine, and
parents become hesitant and reluctant to accept the vaccine (Price, 2017; Stokley, 2013).
The need for this project was identified through a microsystems assessment of an urban
clinic in South Central Texas, performed to identify the current and potential health issues within
the practice. The clinic currently provides care for 2845 patients from birth till the age of 18
years, of which 766 are males, age 11 to 18 years (target population). Of these patients, it was
determined that roughly 13% or 104 males had been vaccinated (receiving at least one or two
HPV vaccinations). Two hundred thirty-eight (31%) were identified as eligible but missed an
opportunity to receive the HPV vaccination. Three hundred and sixty (47%) were identified as
eligible but missed an opportunity to receive the HPV vaccination. The remaining 39% or 302
patients are either unvaccinated and still needing HPV or has no vaccination records.
Additionally, the need for this project was supported by a press release from the CDC (2013a)
which urged all healthcare providers to work with state and local health providers to increase the
utilization of the HPV vaccine.
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Readiness for Change and Stakeholder Engagement
Assessing an organization’s readiness for change is crucial for quality improvement
projects (Weiner, 2009). The use of Lewin’s Change Theory (Lewin, 1951) has been especially
beneficial in not only creating awareness but in providing education as to why a change is
needed. A readiness for change survey was conducted among the clinical (Medical Assitant,
License Vocational Nurse, Physicians) and non-clinical staff (clinic manager and immunization
coordinator) at the site, using the Change Readiness Survey (Worklife Design, 2008) (see
Appendix A). A total score of 80 was obtained, indicating that the clinic is ready for a change. In
addition to the survey, the staff members were receptive to the project, and no behavioral
resistance was identified. Lastly, the clinic manager and providers were committed and
supportive of any change effort. To be successful with implementing an organizational change,
the support of managers at all levels of the organization is critical (Tanner, 2017). The healthcare
providers at the clinical facility, as well as the CEO of the organization were supportive of this
evidence-based project and the plan to implement the educational toolkit at other clinics within
the practice (C. Moreno, personal communication, March 21, 2017).
Project Identification
Purpose
The purpose of this quality improvement project is to increase the HPV vaccination rates
among males age 11-18 years in a small urban private pediatric clinic in South Central Texas
through the implementation of an evidenced-based HPV Immunization Toolkit. The overall goal
is to increase the HPV vaccination rates in order to reduce the incidence of HPV-associated
diseases. Improving the HPV vaccination rate is a public health priority, more importantly,
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improving vaccination coverage is critical for reducing the incidence of HPV-associated diseases
(Allison, Dunne, Markowitz, O'Leary, Crane, Hurley, & ... Kempe, 2013).
Interventions
The interventions (see Table 1) of this quality improvement project were as follows:
Table 1
Interventions and Actions
Intervention

Provider Actions

HPV immunization

100 % of Healthcare Provider (HCP) participants will

educational toolkit

complete a pre-test and post-test about HPV, HPV vaccine
benefits, risks, immunogenicity and vaccine timing

100 % of HCP participants will verbalize awareness of
resources available to enhance the uptake of the HPV vaccine.

100% of the HCP participants will be more comfortable
with engaging in conversations with patients about HPV and
provide facts about vaccination.

Electronic health
record flagging/reminder

HCP recommendation of HPV vaccine to eligible patients
will increase.

system
Note. HCP = Health Care Providers. HPV= Human Papillomavirus.
Objectives
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The above interventions will facilitate meeting the following project objectives:
1) Increase the uptake of HPV immunization among male patients between ages
11-18 years from 13% to 50% by August 11, 2017.
2) Increase Healthcare Providers’ recommendations to parents/patients for ontime HPV vaccination in adolescent males by 30% from baseline post-intervention.
3) Improve Healthcare Providers’ knowledge of HPV / HPV vaccine post toolkit
intervention.
Rationale. ACIP recommends that the HPV vaccine is routinely given during the
adolescent years, as HPV antibody titers are significantly increased in 12 to 16-year-olds if they
receive the vaccine before initiating sexual activity (Dunne et al., 2014). Current HPV
compliance rate for 11 to 18-year-olds at the clinic averages about 13%, which is well below the
Healthy People 2020 goal of 80% (DHHS, 2015).
Summary and Strength of the Evidence
The review of available resources indicates that the human papillomavirus affects both
males and females and is responsible for an astounding percentage of cervical cancers,
anogenital cancers, oropharyngeal cancer, and genital warts (Dunne et al., 2014; Spleen et al.,
2012). There are various types of HPV which are responsible for various types of diseases.
According to Dunne and colleagues (2104), mucosal HPV can be classified as high-risk or lowrisk. HPV types 16 and 18 are both high risk and are responsible for most cases of cervical
cancer (90%), vaginal cancer (55%), vulva, penile, and anal cancer (79%) (Dunne et al., 2014).
HPV types 6 and 11 are low-risk and are responsible for anogenital warts (Dunne et al., 2014).
There are serious short-term as well as long-term consequences of not vaccinating adolescent
males against the HPV virus prior to exposure. The short-term consequences are most commonly
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associated with genital wart outbreaks (Giuliano, Palefsky, & Goldstone, 2011). The long-term
consequences of HPV infection are different forms of cancer which include oral cancer,
pharyngeal cancer, anal cancer, and penile cancer (CDC, 2016c)
The HPV vaccination is safe and highly effective, especially when administered prior to
HPV exposure (Dobson, McNeil, Dionne, Dawar, Ogilvie, Krajden, & Young, 2013; Spleen et
al., 2012). There have been three vaccines licensed by the FDA which can protect against the
types of HPV responsible for the majority of HPV-related cancers. These are the bi-valent
vaccine (Cervarix), quadrivalent vaccine (Gardasil), and nine-valent vaccine (Gardasil 9) (CDC,
2016a; Spleen, Kluhsman, Clark, Dignan, & Lengerich, 2012). However, in 2014, the bi-valent
and quadrivalent vaccines were discontinued and replaced with the nine-valent vaccine (9vHPV)
due to the provision of additional coverage capacity. (Campos-Outcalt, 2016; Petrosky,
Bocchini, Hariri, Chesson, Curtis, Saraiya, & Markowitz, 2015).
The nine-valent vaccine is recommended for females between the age of 9 to 26 years
and age 9 through 15 years for males (Campos-Outcalt, 2016; Petrosky et al., 2015). The ninevalent HPV vaccine (9vHPV) has been proven and tested to provide effective protection and
coverage against HPV types 6, 11, 16, and 18, the types targeted by the quadrivalent HPV
vaccine (4vHPV), as well as five additional types of HPV, types 31, 33, 45, 52, and 58 (Petrosky
et al., 2015); the most common types of oncogenic HPV found to cause cervical cancer,
anogenital cancers, oropharyngeal cancer, and penile cancer (Denny, 2012; Yang & Bracken,
2016). Despite the availability of this effective vaccine, some barriers to successful vaccination
of adolescents still exist. These include decreased knowledge about the HPV vaccine, concerns
about the vaccine’s safety, lack of provider recommendation for the vaccine, cost of vaccination,
lack of follow-up appointments to complete the series, and lack of access to the vaccine (Conroy,
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Rosenthal, Zimet, Jin, Bernstein, Glynn, & Kahn, 2009; Rahman, Laz, McGrath, & Berenson,
2015). Rahman et al., (2015) in a study of 23,564 patients with provider-verified HPV
vaccination records, noted that parental HPV vaccine awareness, parental acceptability, and
provider recommendation are key factors for higher HPV vaccine uptake among adolescents
(Rahman et al., 2015). However, results from this study revealed that provider recommendation
has the strongest influence on increasing both initiation and series completion of the vaccine
(Rahman et al., 2015).
Recent evidence has shown that the implementation of a multi-component intervention to
include strong provider recommendation, HPV-specific educational brochures, along with a
reminder systems for healthcare professionals, can increase both the uptake and completion of
the HPV vaccine series (Tiro, Sanders, Pruitt, Stevens, Sugg, Skinner, Bishop, Fuller, & Persaud,
2015). Tiro and colleagues (2015) in a study of 875 parent/guardians of unvaccinated girls aged
11 to 18 years demonstrated that a multifaceted approach was an effective method to improving
both uptake and completion of the HPV vaccine (Tiro et al., 2015).
Lastly, there has been increased awareness of the need to improve HPV immunization
rates nationally and statewide, because HPV is one of the most commonly acquired STIs and one
of the most expensive to diagnose and treat, partly because of the volume of new infections that
are diagnosed annually (Daley, 2011). Many adolescents will be exposed to HPV within the first
year of becoming sexually active (Daley, 2011). As a result, the need to improve HPV
vaccination rates among adolescent males in effort to prevent HPV-related disease is more
important than ever especially because it has become a public health issue that needs to be
addressed promptly (Daley, 2011). Therefore, an HPV vaccination intervention, which
incorporates healthcare provider (HCP) recommendations and parent education, explicitly
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highlighting the importance and benefits of the HPV vaccine in males, should be considered and
implemented in an effort to increase the rate of HPV immunization among the adolescent male
population (Rahman et al., 2015)
Methods
The outcome of this evidenced-based quality improvement project is its influence on the
rate of compliance with HPV vaccination, which was determined by measuring pre-and postvaccine rates, provider HPV knowledge, and missed opportunities for vaccination. The education
component of this QI project was proposed to last for 8 weeks at 30 minutes per session,
administered in a classroom setting on a biweekly basis. However, due to time constraints and a
shortage of staff at the clinic, the project implementation was adjusted to one 45 minute session
in the classroom and one-on-one sessions with the medical assistants and LVNs as needed.
Each session was comprised of information which focused on addressing issues related to
HPV. These sessions utilized open discussion, PowerPoint® presentations and online resources,
facts about HPV-associated diseases, and HPV vaccine recommendations and schedule.
Instruments
The CDC “You Are the Key to HPV Prevention” PowerPoint and pre-test/post-test
questionnaire, were used for this study. The CDC tool is considered a reliable tool used in
various HPV prevention intervention and projects (CDC, 2017b). Demographic information on
race, gender, age, insurance, and type of visit were collected.
Project Design
The project was a multi-phase project that included retrospective chart reviews in order to
determine the HPV vaccine uptake rate for the target population within the practice. The first
retrospective review period was January 1, 2017, through May 31, 2017, to establish the
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practice’s current HPV vaccine rate among adolescents. After the collection of baseline data, an
HPV immunization educational toolkit was implemented using elements of the CDC’s “You are
the Key to HPV Prevention” resources and promotional materials provided by Merck, the
manufacturer of the HPV vaccine. Additionally, an electronic alerts system was integrated into
the clinic's current electronic health record to notify providers when a patient was due for the
HPV vaccine. The last phase of the project was the evaluation of the effectiveness of the toolkit
using a pre-test and post-test questionnaires as well as a second retrospective chart review of
adolescent males seen in the clinic from June 1, 2017, through August 11, 2017, to measure the
impact of the intervention on HPV immunization rates.
Setting and Population
The setting for this quality improvement project was a small private pediatric practice in
an urban location with three healthcare providers, three LVNs, and five MAs. The target
population for this project consisted of male patients, 11 to 18 years of age. Patient age was
restricted to 11 to 18 years based on the clinic’s policy and guidelines on when the HPV vaccine
is to be offered to patients. A retrospective chart review of 100 male patients, age 11-18 years
old, was conducted from a database of active male patients in the practice who met eligibility
criteria during the review periods to determine the clinic’s current rate of HPV vaccination. The
electronic health record was also used to identify, verify, and track HPV vaccine status of
subjects who met eligibility criteria and to obtain patient demographics including age, gender,
and race. Inclusion criteria included
1. Patients with an ICD-10 code for a well-child exam (Z00.129).
2. Patients with an ICD-10 code for HPV vaccination (Z23).
3. Active patients seen at the clinic within the last two years.
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Exclusion criteria included:
1. Patients with no contact information
2. Patients who had not been seen in the clinic for more than two years.
3. Patients who had an HPV vaccine contraindication.
Project Intervention
The University of the Incarnate Word’s Institutional Review Board (IRB) granted
approval for this project (IRB Record Number 17-05-007) (see Appendix C). Informed consent
(see Appendix B) was obtained from HCPs who agreed to participate in the education
component of the toolkit.
Toolkit. Based on a literature review of HPV vaccine uptake, predictors of vaccination,
and barriers to vaccination in young males, an immunization educational toolkit that consisted of
two separate parts was developed. The components of the toolkit were:
• An evidence-based resource manual for healthcare providers that provides facts
regarding HPV, HPV-related diseases, and the HPV vaccine.
• Promotional materials including posters and a brochure entitled “4 Things
Parents Need to Know About HPV” by Merck.
After finalization of the educational PowerPoint® presentation, obtaining the facts
brochure and before implementation of the intervention, items were reviewed to assure a reading
level of sixth grade or lower as determined by Microsoft Word® proofing measures.
Additionally, the project mentor and the CEO of the clinic reviewed the toolkit for ease of
reading and the overall impact of the presented information. A 45-minute training that included
general information about HPV and the HPV vaccine, using the CDC’s “You are the Key to
HPV Cancer Prevention” PowerPoint® presentation, as well as the protocol for the use of the
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HPV facts brochure “4 Things Parents Need to Know about HPV” was given to participants.
Participants who participated in the training and completed a pre-test and post-test evaluation
received free breakfast for time spent contributing to the project. Access to the resource manuals
and promotional materials presented during the training was made available to staff for future
references.
Parents of boys who presented for an office visit received the initial recommendation for
HPV vaccine from the MA and were given the HPV facts brochure after vitalization and
rooming for the visit. Providers were prompted by a note written by the MA on the
communication board posted at the entrance of each exam room, providing a cue to action to
complete a brief one-on-one intervention with the parent/guardian, if the recommendation for the
vaccine by the MA was declined. If consent was obtained, the HPV vaccine was given, and the
parent/guardian was given a reminder card and encouraged to schedule an appointment for the
following dose before leaving the office.
Reminder System. An electronic alerts system was integrated into the clinic’s current
electronic health record which triggers a pop-up reminder message whenever patient charts are
activated by any of the clinic’s HCPs or staff. The alert signals the personnel that the patient is
due for a 1st, 2nd, or 3rd dose of the HPV vaccine. At that time, the staff acknowledge the alert
by clicking “OK” in order to continue in the chart. The first step after the acknowledgment is the
initiation of the vaccine recommendation by the MAs. The second step was documentation of the
recommendation in the electronic health record. The Mas document whether the
recommendation was given and if it was accepted or declined by parent/guardian. The reasons
for declining the vaccine were documented as well. The final step was the provider’s
documentation of the recommendation. Each provider documented under the immunization
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section the following whether the HPV recommendation was given, the parent/guardian’s
acceptance or declination and the reason for declination, if applicable.
Evaluation
The evaluation of the intervention for this quality improvement project included:
• Pre-test and post-test evaluation of the education component;
• Two retrospective chart reviews completed pre-intervention (January 1, 2017
May 31, 2017) and post-intervention (June 1, 2017 – August 11, 2017).
The pre-test and post-test evaluations (see Appendix E) contained seven multiple-choice
questions that assessed multiple dimensions of the participants’ knowledge on HPV and one
question on a Likert scale to assess providers’ willingness to recommend the vaccine. Possible
scores range from 1 to 7, with higher scores indicating a higher level of knowledge on HPV.
Variables
This project had two interventions that were evaluated with four separate outcome
variables. The interventions were 1) the education module that was part of an HPV immunization
toolkit and, 2) the electronic alert system. The outcome variables were HCPs knowledge about
the HPV vaccine, the willingness of HCPs to recommend the HPV vaccine to their patients,
missed opportunities, defined as instances when the HPV vaccines should have been
administered but were not, and HPV vaccine rates of adolescent males, age 11 to 18 years, pre
and post-intervention.
Barriers and Facilitators
There were a number of barriers and facilitators identified that proved to be either a
hindrance or aid in the intervention process (see Table 2). Some barriers were organizational
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issues (i.e., allotted time for visits and rules regarding posters within the facility) that are outside
of the realm of this quality improvement project.
Table 2
Barriers and Facilitators
Barriers
•

•

Providers have limited time to discuss

(10 minutes slot per visit).

clinics within the organization

There are no flyers or posters to

•

The clinic uses public/private assistance

highlight HPV and the HPV vaccine in

programs (TVFC) to help pay for the cost

the waiting room, the exam rooms, or

of the vaccine.
•

Newer staff have limited knowledge of

There is no administration fee for a
vaccine for uninsured patients.

•

The clinic has an assigned immunization

guidelines.

LVN that keep track of all immunization

The clinic has a high staff turnover rate,

stock, audits vaccination rate and order

leading to a lack of continuity of care

vaccines and supplies needed.

and a huge knowledge gap which results
in decreased recommendations.
•

The low rates of HPV vaccination are a
concern, not only for this clinic but other

the HPV schedule and recommendation

•

•

HPV vaccine due to competing priorities

other areas of the clinic premises.
•

Facilitators

Low stock of HPV vaccine results in
decreased recommendations.

Note. TVFC = Texas Vaccines for Children Program
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Ethical Considerations
Human papillomavirus is a disease that affects men and women worldwide. Sociocultural disparities related to HPV persist, with the most disadvantaged men experiencing twice
the incidence of HPV-related cancers, especially since there are no screening programs available
for men (CDC, 2017a). However, research indicates that males are an essential factor in the
transmission of the HPV virus between people. Therefore, it is ethical to encourage vaccination
in this population (Navarro-Illana, Aznar & Díez-Domingo, 2014). According to a study by
Zimet, Rosberger, Fusher, Perez, and Stupiansky (2013), one concern expressed by parents of
young adolescents, when encouraging or advocating for the HPV vaccine, is that the HPV
vaccine will lead to engagement in sexual activity at a younger age without using safe sex
behaviors. However, targeting this vulnerable age group can potentially improve the vaccine
rates of boys before sexual debut.
Results
Descriptive statistics were used to describe the participants and results for the various
components of the project. Figure 1 describes the healthcare providers (HCPs) who participated
in the education component of the intervention.
Patient Demographics
Of the 100 male patient charts reviewed, the majority of the patients (58%) were
Hispanic, 13% White, 12% African American, 3% Middle Eastern, 2% Asian, and 2%
undocumented (see Figure 2). The vast majority of the patients were covered by government
programs (85%), 5% were uninsured, and 10% had private insurance (see Figure 3).
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Figure 1. Characteristics of participants in the education component.

Figure 2. Patient demographics
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Figure 3. Patient insurance.
Healthcare Provider Knowledge
Healthcare Provider knowledge was measured before and after participating in the
education component of the HPV immunization educational toolkit. Out of the five MAs who
completed the pre-test survey before the education component, two MAs (40%) had a score
greater than 6 indicating good knowledge of HPV and the HPV vaccine, two out of three LVNs
(67%) had a score greater than 6 on the pre-test. On the post-test, four out of five MAs (80%)
had a score greater than 6, and two out of three LVNs (67%) score greater than 6. The largest
improvement in HCP knowledge was seen among the MAs. There was no change among the
LVNs.
Provider Willingness to Recommend
When answering the question “How likely are you as a healthcare provider to routinely
recommend the HPV vaccine to patients with the other required vaccinations?” 66.7% of HCPs
responded with an answer of “strongly agree” or “agree” on the pre-tests, and 100% responded
positively on the post-tests. A net change of 33.3% was seen between pre-education and posteducation responses.
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Figure 4. HCP’s knowledge.
Documentation of HPV Vaccine Recommendation
Currently, there is not a specific location in the clinic’s EHR to document any counseling
or recommendations given. However, a few providers wrote in their notes when HPV counseling
or recommendations were given, especially when the patient or parent declined or deferred
vaccination. Of the 100 patient charts reviewed, 18 (18%) had documentation of counseling on
the HPV vaccine during the visit.
Initiation of HPV Vaccine
The primary outcome of HPV vaccine uptake, which was recorded as a dichotomous
response of yes or no, was measured through retrospective chart reviews. At this primary care
clinic from June 1, 2017, to August 11, 2017, most visits were for well-child exams and routine
physicals. This visit profile was expected because the review period occurred in the summer
leading up to the start of new school year.
As shown in Table 3, 100 charts were reviewed with 26 boys falling into the
recommended age group for HPV vaccination (11 to 12 years old) and 74 falling into the catch-
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up age group for HPV vaccination (13 to 18 years old). A total of 62 adolescent males of the
sample received their first dose of the HPV vaccine during the measurement period.
Table 3
Post Intervention Chart Review
Age (n = 100)

Vaccine Rate (n = 100)

Target

Vaccine Given

62

Vaccine Not Offered

31

Vaccine Refused

7

11-12 Years

26

Catch up
13-18 Years

74

Pre- and Post-Intervention Results
Figure 5 shows that there was a significant increase in the HPV vaccination rates of
adolescent males (48.4%) from the collection of preliminary data (January 2017) to the end of
the project (August 2017). It also reveals a decrease of 42 % in missed opportunities during this
same time frame. Lastly, there was an increase in Healthcare Provider knowledge of 20.5%.
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Figure 5. Pre and post intervention results summary.

Discussion
Limitations
The major limitation of this DNP project was the limited time frame for implementing the
study and gathering data. The chart reviews were completed during summer break (June and
July). However, the months of August and early September are the most popular for adolescents
to see their HCP and receive other mandated adolescent vaccines before starting school. An
additional limitation is the clinic’s history of high turnover rates of some personnel, which
impacted the participation and education of these HCPs. The newly hired MAs, after the
implementation of the education portion of the intervention, were not given the opportunity to
participate in the HPV immunization educational toolkit, which may have impacted vaccine
uptake.
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Recommendations
The fact that the immunization rate improved significantly after implementation of the
toolkit suggests that this multi-component intervention, which included education, HCP
recommendation, and an electronic alert system, was enough to provide a significant
improvement in the vaccination rate among the chosen population. Also, while evidence exists to
indicate that provider recommendations are key to the acceptance of the HPV vaccine, most
often providers forget to recommend the vaccine due to the rapidly evolving and heavily loaded
patient schedule. This study proved that an electronic clinical alert is an effective way to remind
providers to recommend the HPV vaccine. A study by Stockwell and Fiks (2013), also found that
implementing a clinical decision support into a clinic’s EHR, which flagged all patients meeting
the eligibility criteria for the HPV vaccine, helped remind providers to make vaccine
recommendations consistently at every visit and improved documentation of recommendations
given, thereby increasing immunization uptake and reducing missed opportunities.
On a system level, manually tracking and documenting the number of patients who
received vaccines and those who did not receive vaccines during an individual visit is
overwhelming. Adapting or incorporating an immunization information software system into the
clinic’s existing electronic health record system that will track and flag patients behind the scene
rather than through individual chart reviews will be much more effective, sustainable and will
offer greater potential to transform the delivery of vaccine at the clinic. It has been shown that
clinic practices that utilize an immunization information system to monitor vaccine compliance
have significantly higher vaccine coverage rates than those practices that do not use an IIS
(Groom, Hopkins, Pabst, Murphy Morgan, Patel, Calonge, & ... Zucker, 2015; Stockwell, &
Fiks, 2013).
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Implications for Practice
This project shows that there is still need for increased education and awareness targeting
parents/guardians and adolescents about HPV and the HPV vaccine. Healthcare Providers should
further research, educate and implement various interventions that can lead to a more informed
U.S. population. The future implications of not vaccinating this target population are too
enormous not to acknowledge and act now.
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Appendix B
Informed Consent Notice
Before consenting to participate in this quality improvement project, it is important that
you read and understand the following explanation of the purpose, benefits, and risks of the
project and how it will be conducted.
Title of Project: Increasing the Vaccination Rates of Adolescent Males 11 to 18 Years of
Age in an Urban Pediatric Clinic. A Quality Improvement Project
Primary Investigator: Victoria Fadare, MPH, BSN, University of the Incarnate World.
Supervising Mentor: Dr. Holly A DiLeo, PhD, University of the Incarnate World.
Your participation is solicited in a study that will evaluate the impact a multi-component
intervention to include, strong provider recommendation, HPV specific educational brochure,
along with reminder systems for healthcare providers, has on increasing the uptake of HPV
vaccine among adolescent males. Effectiveness of this intervention will be determined by
increased HPV knowledge among healthcare providers, strong provider’s recommendation of
HPV vaccine to eligible adolescent patients, and ultimately an increase in adolescents who
receive the HPV vaccine.
Your participation in the study, which is optional, involves you as the healthcare provider
participating in educational presentation and competition of a pre-test and post-test survey. Total
time to complete the education section, pre-test and post-test evaluations should not exceed 2
hours.
There are no anticipated risks involved with participation in this study.
Benefits for study participants may include increased knowledge about the HPV vaccine
and increased uptake of the HPV vaccine among adolescents. We hope to learn more about how
the interventions in this study impact the number of adolescents willing to accept the HPV
vaccine.
The confidentiality of your individual identifying information will be maintained in any
write up or presentations made regarding this study. Identifying information will be limited to
your position held in the clinic (MA, LVN, MD, or NP). All survey results will remain
confidential.
Any questions about the study should be directed to Victoria Fadare at
fadare@student.uiwtx.edu , Dr. Holly DiLeo at dileo@uiwtx.edu.
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Your participation in the study confirms that you have read the above information and agree
to the following:
•
•
•

You have a good description of the study and have been given the opportunity to ask
questions about the study.
You are aware of the fact that involvement in the study is voluntary and refusal to
participate or the decision to leave the study at any time involves no penalty to you or
loss of rights or benefits. You understand your rights and voluntarily agree to participate.
You understand that you are free to keep a copy of this form for your records.
__________________________________________
Name of study participant
__________________________________________
Signature of study participant

_______________
Date
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Appendix C
IRB APPROVAL
May 8 2017
PI: Mrs. Victoria Fadare
Protocol title: Increasing the Vaccination Rates of Adolescent Males 11 to 18 Years of
Age in a Urban Pediatric Clinic
Victoria:
Your request to conduct the study titled "Increasing the Vaccination Rates of Adolescent
Males 11 to 18 Years of Age in a Urban Pediatric Clinic" was approved by Exempt review on
05/08/2017. Your IRB approval number is 17-05-007. Any written communication with potential
subjects or subjects must be approved and include the IRB approval number.
Please keep in mind these additional IRB requirements:
 This approval will expire one year from 05/08/2017.
 Request for continuing review must be completed for projects extending past one year. Use
the IRB Continuing Review Request form.
 Changes in protocol procedures must be approved by the IRB prior to implementation except
when necessary to eliminate apparent immediate hazards to the subjects. Use the IRB
Amendment Request form.
 Any unanticipated problems involving risks to subjects or others must be reported
immediately.
Approved protocols are filed by their number. Please refer to this number when
communicating about this protocol.
Approval may be suspended or terminated if there is evidence of a) noncompliance with
federal regulations or university policy or b) any aberration from the current, approved protocol.
Congratulations and best wishes for successful completion of your research. If you need
any assistance, please contact the UIW IRB representative for your college/school or the Office
of Research Development.
Sincerely,
Ana Wandless-Hagendorf, PhD, CPRA
Research Officer, Office of Research Development
University of the Incarnate Word
(210) 805-3036
wandless@uiwtx.edu
Page 1 of 1
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Appendix D
Authorization letter to use CDC’s “You Are the key to HPV Cancer Prevention”
From: Preteen Vaccines (cdc) (CDC) <preteenvaccines@cdc.gov>
Sent: Tuesday, April 25, 2017 2:11:33 PM
To: Victoria Delano
Subject: RE: Request for English HPV You Are the Key slides
Hello,
Attached you will find CDC’s English “You Are the Key to HPV Cancer Prevention:
Understanding the Burden of HPV-Related Cancers” slide set. Please feel free to use this
presentation as is or customize it for your audience. As long no additional slides are added, you
can keep the template with the logos on it. It’s fine to remove slides or hide slides to reduce the
time/size of the presentation. If the slides are used piecemeal—if they are removed to use with
other slides—we just ask that you put them in your own template.
Also make sure to visit www.cdc.gov/ HPV for ready-to-use tools and resources to
successfully communicate with parents about HPV vaccination. If you have any questions,
contact us, we are more than happy to help.
Thanks for your interest!
CDC’s Adolescent Vaccination Team

From: Victoria Delano [mailto:vdelano@galencollege.edu]
Sent: Thursday, April 6, 2017 4:02 PM
To: Preteen Vaccines (cdc) (CDC) <preteenvaccines@cdc.gov>
Subject: Request for English HPV You Are the Key slides

Hello,
I would like to request for the English version of this PowerPoint® slides. I am a DNP
student working on improving the uptake of HPV vaccine in my clinic. Thank you.
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Appendix E
HPV – You are the Key to HPV Cancer Prevention Toolkit Pre &post-Test
I am a (circle one): MD, PA, ARNP, RN, LVN, and MA
1. How many new cases of HPV are expected to occur each year?
a. 14,000
b. 14,000,000
c. 140,000
d. 1,400,000
2. Why is the quadrivalent HPV vaccine recommended for male patients?
a. To prevent infection with HPV types 6, 11, 16, and 18
b. To prevent genital warts caused by HPV types 6 and 11
c. To prevent anal cancer that is caused by HPV types 16 and 18
d. To prevent infections caused by HPV 6, 11, 16, and 18 and to prevent genital warts
and anal cancer.
3. Which recommendation for 11 to 12-year-olds is likely to be most successful?
a. Ask about the sexual activity of the child prior to discussing the HPV vaccine
b. Inform the parent that their child is due to receive three scheduled vaccines: HPV,
MCV4, and Tdap.
c. Inform parents those mandatory vaccines that are required for school attendance and
ask if they also want to get the HPV vaccine.
d. Give the parents the option of vaccinating their child now with the HPV vaccine or
waiting until the child is older.
4. The HPV vaccine is suggested for which patients?
a. Male and female adolescents at the 11 or 12-year-old visit
b. Females only at the 13-year-old well child visit
c. Males only at the 11 and 12-year-old visit
d. Females only at the 11 and 12-year-old visit
5. Which three goals are evidence-based and important to teach parents?
a. HPV vaccine prevents STD’s, is most effective when started after sexual activity, and
it is important to get all 3 shots on time
b. HPV vaccine is a cancer prevention vaccine, it is most effective when given to 11 and
12-year-olds, and it is important to get all 3 shots
c. It important to get at least 1 of the 3 shots, HPV vaccine is a cancer prevention vaccine,
and it should be started after sexual activity
d. HPV vaccine prevents genital warts, it should be started at 11 and 12 years of age, and
it is most important to get the first shot in the series
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HPV – You are the Key to HPV Cancer Prevention Toolkit Pre &post-Test –
continued
6. What is the single best predictor of a decision to vaccinate?
a. A strong recommendation by the healthcare provider
b. Strong recommendations from friends and family to get the vaccination
c. Hearing about the vaccine on the TV or radio
d. Reading about the vaccine in a brochure or on posters
7. Why is the HPV vaccination recommended to be given to 11 and 12-year-olds?
a. The HPV vaccine provides the strongest immune response when given at that
age
b. It is convenient to give with other required vaccines for school
c. Older children are used to getting vaccines
d. Both A and B
8. What age range is considered “permissive” for catch-up immunizations for HPV
vaccines?
a. It is permissive to vaccinate males and females only at the 11 and 12-year-old
appointments
b. It is permissive for females only to be vaccinated between 9 and 26 years old
c. It is permissive for only males only to be vaccinated between 9 and 26 years old
d. It is permissive for both males and females to be vaccinated between 9 and 26 years
old
9. All of the following are true about missed opportunities except:
a. Review immunization records at acute care visits
b. Provide the vaccine at pre-sports and camp physicals
c. Give the HPV vaccine with other routine adolescent vaccines
d. Rely on the parents to keep immunization records accurate and know when vaccines
are due
10. How likely are you as a healthcare provider to routinely recommend the HPV vaccine
to male and female patients with their other required vaccinations?
a. Strongly Agree
b. Agree
c. Somewhat Agree
d. Neutral
e. Somewhat Disagree
f. Disagree
g. Strongly Disagree

